• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol. Development of epitope-based peptide vaccine against novel Coronavirus 2019 (SARS-COV-2): Immunoinformatics approach

tetano

Editor, Senior Moderator
J Med Virol. 2020 Feb 28. doi: 10.1002/jmv.25736. [Epub ahead of print] [h=1]Development of epitope-based peptide vaccine against novel Coronavirus 2019 (SARS-COV-2): Immunoinformatics approach.[/h]
Bhattacharya M[SUP]1,[/SUP][SUP]2[/SUP], Ranjan Sharma A[SUP]1[/SUP], Patra P[SUP]2[/SUP], Ghosh P[SUP]2[/SUP], Sharma G[SUP]3[/SUP], Chandra Patra B[SUP]2[/SUP], Lee SS[SUP]1[/SUP], Chakraborty C[SUP]1,[/SUP][SUP]4[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Recently, a novel Coronavirus (SARS-COV-2) emerged which is responsible for the recent outbreak in Wuhan, China. Genetically, it is closely related to the SARS-CoV and MERS-CoV. The situation is getting worse and worse, therefore, there is an urgent need for designing a suitable peptide vaccine component against the SARS-COV-2. Here, we characterized spike glycoprotein to obtain immunogenic epitopes. Next, we chose 13 Major Histocompatibility Complex-(MHC) I and 3 MHC-II epitopes, having antigenic properties. These epitopes are usually linked to specific linkers to build vaccine components and molecularly dock on Toll-Like Receptor (TLR)-5 to get binding affinity. Therefore, in order to provide a fast immunogenic profile of these epitopes we performed immunoinformatics analysis so that rapid development of vaccine might bring this disastrous situation to the end earlier. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.


[h=4]KEYWORDS:[/h] SARS-COV-2; epitopes; immunoinformatics; vaccine

PMID: 32108359 DOI: 10.1002/jmv.25736
 
Back
Top